Report of Foreign Issuer (6-k)
March 12 2018 - 4:34PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13a-16 or 15d-16
UNDER
THE SECURITIES EXCHANGE ACT
of 1934
For the Month of March 2018
001-37521
(Commission File Number)
INTEC PHARMA LTD.
(Translation of registrant’s name into English)
12 Hartom Street
Har Hotzvim, Jerusalem 9777512, Israel
(+972) (2) 586-4657
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover
Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(l): _________
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): _________
EXPLANATORY
NOTE
On March 12, 2018, Intec Pharma
Ltd. issued a press release titled “Intec Pharma Partners with LTS for Manufacture of Accordion Pill Carbidopa/Levodopa for
Treatment of Parkinson’s Disease.”
A copy of the press release
is attached hereto as Exhibit 99.1 and incorporated by reference hereto.
This Form 6-K incorporated
by reference into the Company’s registration statements on Form S-8 (Files No. 333-209700, No. 333-212801 and No.
333-222217) and Form F-3 (Files No. 333-217189 and No. 333-218539).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
INTEC PHARMA LTD.
|
|
|
|
|
|
|
By:
|
/s/
Nir Sassi
|
|
|
|
Name: Nir Sassi
|
|
|
|
Title: Chief Financial Officer
|
|
|
|
Date: March 12, 2018
|
|
|
|
EXHIBIT
INDEX
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Apr 2023 to Apr 2024